Locations
Cambridge, MA, USA · Cambridge, MA, USA
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Series A
founded in
2019
Myeloid Therapeutics is an immunology company that leverages advanced gene and cell therapy methods to develop mRNA-based immunotherapies targeting myeloid cells for cancer treatment. Their innovative platform technologies, including in vivo programming and gene editing, aim to enhance anti-tumor immunity and improve patient outcomes. With a clinical-stage pipeline focused on breakthrough therapies for cancers like glioblastoma and T cell lymphoma, Myeloid is positioned to make significant strides in the oncology market. The company has received Fast Track Designation from the US FDA and has established collaborations to enhance its research and development capabilities.
Something looks off?On-site & Remote